Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)
ID: 347497Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $100K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347497

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-160.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)," aimed at enhancing clinical trial readiness for rare diseases. This initiative invites applications for small grants to support research that addresses critical needs in advancing therapeutics towards clinical trials, focusing on the development of biomarkers and clinical outcome measures to improve success rates. The funding is particularly important for elucidating the presentation and progression of rare diseases, with a budget cap of $100,000 over a two-year project duration. Interested applicants, including various educational institutions and nonprofit organizations, must submit their proposals by October 17, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-160-Full-Announcement.html
    PAR-23-160.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity aimed at enhancing clinical trial readiness for rare diseases, disorders, and syndromes. The initiative invites applications for small grants (R03) that facilitate research addressing crucial needs in moving therapeutics towards clinical trials. The focus is on developing biomarkers and outcome measures to improve success rates in clinical trials. This funding opportunity targets projects that elucidate the presentation and progression of rare diseases or utilize sensitive tools for participant selection and effect measurement. Proposals should leverage existing research resources and have a project duration of up to two years, with a budget cap of $50,000 per year. Eligible applicants include various educational institutions, nonprofits, and government entities. The review process emphasizes the significance of the problem addressed, the investigator's capability, and the innovation of the approach. Applications that do not directly correlate with rare diseases or propose clinical trials will be deemed non-responsive. The deadline for the first round of applications is set for May 2023, with subsequent dates throughout 2024.
    Similar Opportunities
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for preclinical proof of concept studies targeting rare diseases under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support efficacy studies in established preclinical models for therapeutic agents, including small molecules and biologics, with the goal of advancing projects toward Investigational New Drug (IND) applications. The funding is particularly significant as it addresses the unmet medical needs of approximately 30 million individuals in the U.S. affected by rare diseases, enhancing the likelihood of progressing novel therapies to clinical trials. The total funding available is up to $1,200,000 for FY26, with a maximum budget of $275,000 per two-year project. Interested applicants must submit their letters of intent by May 1, 2025, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.html.
    NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the Small Research Grant Program (Parent R03 Clinical Trial Not Allowed), aimed at supporting discrete research projects that can be completed within two years and require limited resources. This program encourages applications for various types of research, including pilot studies, feasibility studies, and the development of new research methodologies, while explicitly excluding clinical trials. With a funding ceiling of $50,000 per year, the program is open to a diverse range of eligible applicants, including higher education institutions, nonprofits, and government entities, particularly those representing historically underrepresented groups. Interested applicants should note that the first submission opportunity opens on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases," aimed at supporting pilot projects that explore the roles of understudied proteins linked to rare diseases. The objective is to generate preliminary data and tools related to these proteins, which are associated with rare diseases affecting fewer than 200,000 individuals in the U.S., thereby facilitating innovative research that could lead to new drug targets and treatments. Eligible applicants include a wide range of institutions, including educational and nonprofit organizations, government entities, and small businesses, with funding available up to $100,000 for projects that can be completed within one year. Interested parties can find more information and apply by contacting NIH Grants Information at grantsinfo@nih.gov, with applications due by November 16, 2027.
    Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" aimed at stimulating innovation in the implementation and sharing of genomic information in clinical care across diverse populations. This initiative encourages applications for small research projects that explore the integration of genomic data into clinical practice, assess barriers to implementation, and develop innovative data analysis techniques, particularly focusing on underrepresented populations in genomic research. The maximum budget for each application is $50,000 over a two-year period, with a total funding expectation of approximately $150,000 for FY 2024. Interested applicants must submit their proposals by February 12, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) to support small-scale research projects that can be completed in a short timeframe with limited resources. This program is designed to fund various types of research, including pilot studies, secondary data analysis, and the development of research methodologies, while explicitly excluding clinical trials. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal governments, with each application allowed to request up to $50,000 per year for a project duration not exceeding two years. Interested parties should submit their applications electronically via Grants.gov by January 7, 2025, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for any inquiries regarding the funding announcement.
    Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" aimed at stimulating innovation in the implementation and sharing of genomic information in clinical care across diverse populations. This initiative seeks proposals that enhance understanding of genomic data applications, assess implementation methods, and identify barriers to health equity, particularly for underrepresented groups. The R03 grant mechanism supports small research projects with a maximum budget of $50,000 per year, with an estimated total funding of approximately $150,000 for two awards in fiscal year 2024. Applications must be submitted electronically by February 12, 2025, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NICHD Small Research Grant Program (R03 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03 Clinical Trial Required) to support clinical trials aligned with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This program aims to fund small-scale research projects, including pilot studies and methodological development, with a maximum budget of $50,000 per year for up to two years. The funding is crucial for advancing knowledge in human development fields, particularly in childhood development and rehabilitation medicine. Interested applicants must adhere to specific guidelines and register with Grants.gov and eRA Commons, with the application window opening on January 16, 2025, and closing on January 8, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.